دورية أكاديمية
أعرض في EDS

Evaluating the Impact of Intensifying Treatment from Human to Analogue Insulin on Glycaemic Control and Insulin Expenditure in Patients with Type 2 Diabetes: A Retrospective Cohort Study.

التفاصيل البيبلوغرافية
العنوان: Evaluating the Impact of Intensifying Treatment from Human to Analogue Insulin on Glycaemic Control and Insulin Expenditure in Patients with Type 2 Diabetes: A Retrospective Cohort Study.
المؤلفون: Hussin SA; Department of Internal Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia., Mohamad NA; Department of Pharmacy, Hospital Universiti Sains Malaysia, Kelantan, Malaysia., Othman MK; Department of Internal Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia., Wan Mohamed WMI; Department of Internal Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia.
المصدر: The Malaysian journal of medical sciences : MJMS [Malays J Med Sci] 2024 Apr; Vol. 31 (2), pp. 159-169. Date of Electronic Publication: 2024 Apr 23.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Universiti Sains Malaysia Press Country of Publication: Malaysia NLM ID: 101126308 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1394-195X (Print) Linking ISSN: 1394195X NLM ISO Abbreviation: Malays J Med Sci Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: [Pulau Pinang, Malaysia] : Universiti Sains Malaysia Press
Original Publication: [Kubang Kerian, Kelantan, Malaysia] : School of Medical Sciences, Universiti Sains Malaysia,
مستخلص: Background: Achieving good glycaemic control is essential to reducing the risk of diabetes complications. Insulin is the most effective therapy for achieving good glycaemic control; however, it is associated with a higher risk of hypoglycaemia, especially with human insulin. This study aimed to evaluate the efficacy of intensification from human to analogue insulin and its added cost.
Methods: This retrospective study was conducted at the Hospital Universiti Sains Malaysia (HUSM). Patients with type 2 diabetes mellitus (T2DM) who underwent intensification for at least 3 months from human to analogue insulin were included in this study. The patients' medical records, haemoglobin A1c (Hba1c) and fasting blood sugar (FBS) were retrieved. The total cost pre- and post-intensification of insulin was obtained from the pharmacy database. Differences in HbA1c, FBS and total insulin cost pre- and post-intensification were analysed.
Results: A total of 163 patients with T2DM who had intensification from human to analogue insulin were included in this study. HbA1c and FBS levels were significantly lower in analogue insulin. However, the differences were not clinically significant, as the mean reduction in HbA1c was less than 0.5%. Meanwhile, the total costs of analogue insulin for 3 months were higher.
Conclusion: There were no clinically significant improvements in patients' HbA1c and FBS after the intensification of insulin, despite the extra costs spent. Hence, it is vital to choose the right group of patients to receive an insulin analogue to maximise its benefit but at the most optimal cost.
Competing Interests: Conflict of Interest: None.
(© Penerbit Universiti Sains Malaysia, 2024.)
References: N Engl J Med. 1993 Sep 30;329(14):977-86. (PMID: 8366922)
Adv Ther. 2008 Aug;25(8):752-74. (PMID: 18704282)
Curr Med Res Opin. 2008 May;24(5):1417-28. (PMID: 18400145)
CMAJ. 2009 Feb 17;180(4):385-97. (PMID: 19221352)
Health Technol Assess. 2010 Jul;14(36):1-248. (PMID: 20646668)
Value Health. 2009 Nov-Dec;12 Suppl 3:S55-61. (PMID: 20586983)
J Med Econ. 2013;16(4):468-78. (PMID: 23384160)
Clinicoecon Outcomes Res. 2020 Jun 22;12:333-343. (PMID: 32606850)
Diabetologia. 2019 Aug;62(8):1349-1356. (PMID: 31177314)
Curr Med Res Opin. 2020 Sep;36(9):1441-1447. (PMID: 32643451)
Adv Ther. 2006 Mar-Apr;23(2):191-207. (PMID: 16751153)
Diabet Med. 2009 Aug;26(8):803-14. (PMID: 19709151)
Diabetes Metab. 2011 Jun;37(3):190-200. (PMID: 21333580)
Health Technol Assess. 2004 Nov;8(45):iii, 1-57. (PMID: 15525480)
J Med Econ. 2010;13(2):212-20. (PMID: 20350145)
JAMA. 2019 Jan 29;321(4):374-384. (PMID: 30694321)
Int J Clin Pharmacol Ther. 2011 Mar;49(3):217-30. (PMID: 21329624)
Int J Clin Pract. 2008 Jul;62(7):1026-32. (PMID: 18489577)
Lancet. 1998 Sep 12;352(9131):837-53. (PMID: 9742976)
Diabet Med. 2003 Oct;20(10):863-6. (PMID: 14510870)
BMJ Open. 2011 Jan 1;1(2):e000258. (PMID: 22021891)
Scand J Public Health. 2011 Feb;39(1):79-87. (PMID: 20688795)
Chin Med J (Engl). 2009 Nov 5;122(21):2540-6. (PMID: 19951567)
Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005613. (PMID: 17443605)
Pharmacoeconomics. 2017 Feb;35(2):141-162. (PMID: 27752998)
Curr Med Res Opin. 2007 Apr;23(4):895-901. (PMID: 17407646)
CMAJ. 2009 Feb 17;180(4):400-7. (PMID: 19221353)
Med J Malaysia. 2010 Sep;65(3):180-6. (PMID: 21939164)
Acta Diabetol. 2009 Mar;46(1):67-73. (PMID: 19030772)
Int J Clin Pract. 2008 Sep;62(9):1344-51. (PMID: 18657196)
فهرسة مساهمة: Keywords: FBS; HbA1c; T2DM; analogue insulin; human insulin; insulin cost difference
تواريخ الأحداث: Date Created: 20240502 Latest Revision: 20240503
رمز التحديث: 20240503
مُعرف محوري في PubMed: PMC11057824
DOI: 10.21315/mjms2024.31.2.14
PMID: 38694591
قاعدة البيانات: MEDLINE
الوصف
تدمد:1394-195X
DOI:10.21315/mjms2024.31.2.14